NAV
$39.16
AUM
$5.4M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.88
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +20.85% | +14.36% | +17.95% | +77.88% | +18.01% | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | ALKS | Alkermes PLC | 5.05% |
| 2 | AXSM | Axsome Therapeutics Inc | 4.96% |
| 3 | XENE | Xenon Pharmaceuticals Inc | 4.50% |
| 4 | ARWR | Arrowhead Pharmaceuticals Inc | 4.47% |
| 5 | NBIX | Neurocrine Biosciences Inc | 4.26% |
| 6 | PTCT | PTC Therapeutics Inc | 4.03% |
| 7 | ARGX | argenx SE ADR | 3.99% |
| 8 | PRAX | Praxis Precision Medicines Inc Ordinary Shares | 3.86% |
| 9 | CNTA | Centessa Pharmaceuticals PLC ADR | 3.83% |
| 10 | SRRK | Scholar Rock Holding Corp | 3.73% |
The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index.
Inception Date: 2022-08-24